A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
Brief description of study
If you have been diagnosed with a cancer involving the uterus, such as serous carcinoma or endometrioid endometrial carcinoma, you may qualify for this study. The main goal of this phase II study is to evaluate the safety of treatment with carboplatin (a cytotoxic chemotherapeutic agent) and Abraxane (a cytotoxic antimicrotubule chemotherapeutic agent) and determine the nature and the degree of toxicities following treatment.
Clinical Study Identifier: s15-01156
ClinicalTrials.gov Identifier: NCTs15-01156
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
